This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Sarepta Should Shut Up About Ebola, Focus on Job No. 1

Sarepta Therapeutics (SRPT - Get Report) disappoints me.

By publicizing its outreach to the U.S. government about an experimental ebola treatment, Sarepta comes off looking like just another opportunistic, self-promoting drug developer. Sarepta isn't wrong to remind the U.S. government about the drug in its freezer which might be effective against the ebola virus, but why talk to the media about it?

If Sarepta's ebola contract with the government is revived, issue a press release on the material news. Until then, the company should emulate the respectable low-key approach taken by Tekmira Pharmaceuticals (TKMR - Get Report) and not the crass, stock-pumping antics of Hemispherx Biopharma (HEB - Get Report) or NewLink Genetics (NLNK - Get Report)

Ebola is big news today, but Sarepta has one job right now: Finishing the eteplirsen regulatory package and delivering it to the FDA for review before the end of the year. Nothing else is more important to Sarepta, shareholders or Duchenne muscular dystrophy (DMD) patients and their families. Talking up ebola sounds like a distraction from Sarepta's priority. It sounds like the company is losing focus.

When a DMD parent frustrated by Sarepta inability to make enough eteplirsen for a compassionate use program reads a sentence like the one below, it's a slap in the face:

Sarepta Therapeutics says it has enough doses of its injectible drug - AVI-7537 - to treat about two dozen patients within a week and could ramp up a supply for another 100 patients within a few months.

Sarepta is trying to recover from a dicey few weeks in which its chief scientific officer was fired for trying to unseat CEO Chris Garabedian. Sarepta's board of directors reportedly took power away from Garabedian and then gave it back, resulting in the replacement of the company's chairman. From the outside, Sarepta looks adrift. Supporters (and yes, I'm one of them) have lost some confidence in the company's ability to get the No. 1 job done.

It's not too late for Sarepta to turn things around, but doing so requires less talking and more doing. My free advice to Garabedian: Shut up about ebola and don't make appearances on CNBC's Fast Money. Instead, deliver the eteplirsen FDA filing on time and start dosing DMD kids with eteplirsen in the confirmatory phase III study. Prepare for the next year's inevitable FDA advisory committee meeting. Ramp up eteplirsen manufacturing to make sure you can meet demand. 

No more promises. Start delivering. 


Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Markets

DOW 17,757.91 +138.40 0.79%
S&P 500 2,077.42 +14.31 0.69%
NASDAQ 5,013.1230 +26.2560 0.53%

Adam's Tweets

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
Real Money Pro

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Trifecta Stocks

Trifecta Stocks analyzes over 4,000 equities weekly to find the elite 1% of stocks that pass rigorous quantitative, fundamental and technical tests.

Product Features:
  • Model portfolio
  • Trade alerts
  • Recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Growth Seeker

Bryan Ashenberg, using sophisticated stock screening and fundamental research, identifies potentially explosive small and mid-cap stocks.

Product Features:
  • Model portfolio
  • Small-cap and mid-cap focus
  • Intraday trade alerts
  • Weekly roundups
Options Profits

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
Top Rated Stocks Top Rated Funds Top Rated ETFs